Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway

Tang Yangbin, Yang Guo, Wu Xiaohou, Quan Zhen

PDF(3446 KB)
PDF(3446 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (10) : 1061-1066. DOI: 10.13406/j.cnki.cyxb.003595
Basic research

Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway

Author information +
History +

Abstract

Objective To investigate the effect of deleted in liver cancer-1（DLC-1） on the proliferation，invasion，and apoptosis of enzalutamide-resistant prostate cancer cells and its mechanism of action. Methods Hμmol/Lan prostate cancer lncap and C4-2 cell lines were cultured in vitro with different concentrations of enzalutamide for more than 6 months，and enzalutamide-resistant cell lines were constructed as lncap-R and C4-2-R. IC50 was measured by CCK-8 assay to verify the successful construction of enzalutamide-resistant cell lines. lncap-R and C4-2-R were transfected by lentivirus to achieve the knockdown and overexpression of DLC-1，and colony formation assay，Transwell assay，and flow cytometry were used to observe the effect of DLC-1 on the proliferation，invasion，and apoptosis of enzalutamide-resistant prostate cancer cells. Results Compared with the control group，the overexpression group showed that DLC-1 significantly inhibited the proliferation and invasion of the two enzalutamide-resistant cell lines. As for mechanism of action，Western blot showed that the expression of DLC-1 was negatively correlated with the expression of Rho protein in both enzalutamide-resistant cell lines. The Rho inhibitor rhosin reversed the reduction in the apoptosis of lncap-R cells due to knockdown of DLC-1. Conclusion DLC-1 can downregulate the expression of Rho protein in drug-resistant cell lines and inhibit their proliferation and invasion.

Key words

deleted in liver cancer-1 / prostate cancer / enzalutamide / Rho protein / proliferation / invasion

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Tang Yangbin , Yang Guo , Wu Xiaohou , et al. Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway. Journal of Chongqing Medical University. 2024, 49(10): 1061-1066 https://doi.org/10.13406/j.cnki.cyxb.003595

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Siegel DA， O’Neil ME， Richards TB，et al. Prostate cancer incidence and survival，by stage and race/ethnicity - United States，2001-2017[J]. MMWR Morb Mortal Wkly Rep，2020，69（41）：1473-1480．
本文引用 [1]
2
Zhou ZE， Xu YY， Li QY，et al. Prognostic significance of a novel indicator （PSApostd3/PSApre）for PSA recurrence in patients after radical prostatectomy[J]. Cancer Manag Res，2019，11：5777-5783．
本文引用 [1]
3
Schmidt-Hegemann NS， Zamboglou C， Mason M，et al. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer[J]. Radiother Oncol，2023，183：109544．
本文引用 [1]
4
Liu PY， Wang WX， Wang F，et al. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer[J]. J Transl Med，2023，21（1）：40．
本文引用 [1]
5
Cheng Q， Butler W， Zhou YL，et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy[J]. Eur Urol，2022，81（5）：446-455．
本文引用 [1]
6
Agarwal N， Azad AA， Carles J，et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer （TALAPRO-2）：a randomised，placebo-controlled，phase 3 trial[J]. Lancet，2023，402（10398）：291-303．
本文引用 [1]
7
Armstrong AJ， Iguchi T， Azad AA，et al. The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic Hormone-sensitive prostate cancer：a post hoc analysis of Arches[J]. Eur Urol，2023，84（2）：229-241．
本文引用 [1]
8
Han H， Wang Y， Curto J，et al. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis[J]. Cell Rep，2022，39（1）：110595．
本文引用 [1]
9
Wang JX， Zeng LL， Wu NS，et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells[J]. Drug Resist Updat，2023，70：100985．
本文引用 [1]
10
Basak P， Dillon R， Leslie H，et al. The Deleted in Liver Cancer 1 （Dlc1） tμmol/Lor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity[J]. BMC Cancer，2015，15：630．
本文引用 [1]
11
Liao YC， Lo SH. Deleted in liver cancer-1 （DLC-1）：a tμmol/Lor suppressor not just for liver[J]. Int J Biochem Cell Biol，2008，40（5）：843-847．
本文引用 [1]
12
Ren GH， Li GR. Tμmol/Lor suppressor gene DLC1：its modifications，interactive molecules，and potential prospects for clinical cancer application[J]. Int J Biol Macromol，2021，182：264-275．
本文引用 [1]
13
Niu N， Ma XJ， Liu HT，et al. DLC1 inhibits lung adenocarcinoma cell proliferation，migration and invasion via regulating MAPK signaling pathway[J]. Exp Lung Res，2021，47（4）：173-182．
本文引用 [1]
14
Mosaddeghzadeh N， Ahmadian MR. The RHO family GTPases：mechanisms of regulation and signaling[J]. Cells，2021，10（7）：1831．
本文引用 [1]
15
Nguyen-Nielsen M， Borre M. Diagnostic and therapeutic strategies for prostate cancer[J]. Semin Nucl Med，2016，46（6）：484-490．
本文引用 [1]
16
Alajati A， D’Ambrosio M， Troiani M，et al. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo [J]. J Clin Invest，2020，130（5）：2435-2450．
本文引用 [1]
17
Alyamani M， Li J， Patel M，et al. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure[J]. Ann Oncol，2020，31（3）：369-376．
本文引用 [1]
18
Bultijnck R， Deforche B， Borrey N，et al. Exercise prescription dose for castrate-resistant prostate cancer patients：a phase I prescription dose escalation trial[J]. World J Urol，2021，39（2）：357-364．
本文引用 [1]
19
Cerasuolo M， Maccarinelli F， Coltrini D，et al. Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer[J]. Cancer Res，2020，80（7）：1564-1577．
本文引用 [1]
20
Chen XL， Liu JH， Cheng LJ，et al. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer[J]. Prostate，2020，80（3）：256-266．
本文引用 [1]
21
Dai C， Heemers H， Sharifi N. Androgen signaling in prostate cancer[J]. Cold Spring Harb Perspect Med，2017，7（9）：a030452．
本文引用 [1]
22
Mukherji D， Omlin A， Pezaro C，et al. Metastatic castration-resistant prostate cancer（CRPC）：preclinical and clinical evidence for the sequential use of novel therapeutics[J]. Cancer Metastasis Rev，2014，33（2/3）：555-566．
本文引用 [1]
23
Wang YY， Chen JY， Wu ZJ，et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it[J]. Br J Pharmacol，2021，178（2）：239-261．
本文引用 [1]

Comments

PDF(3446 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉